
Global Gastro Esophageal Reflux Disease (GERD) Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Gastro Esophageal Reflux Disease (GERD) Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Gastro Esophageal Reflux Disease (GERD) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Gastro Esophageal Reflux Disease (GERD) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Gastro Esophageal Reflux Disease (GERD) Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Gastro Esophageal Reflux Disease (GERD) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Gastro Esophageal Reflux Disease (GERD) Drug market include Addex Therapeutics, Aros Pharma, AstraZeneca, Plc., Medtronic, Takeda Pharmaceutical Company Limited, The Kroger Co., GlaxoSmithKline, Pfizer and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Gastro Esophageal Reflux Disease (GERD) Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastro Esophageal Reflux Disease (GERD) Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastro Esophageal Reflux Disease (GERD) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastro Esophageal Reflux Disease (GERD) Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastro Esophageal Reflux Disease (GERD) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastro Esophageal Reflux Disease (GERD) Drug sales, projected growth trends, production technology, application and end-user industry.
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Company
Addex Therapeutics
Aros Pharma
AstraZeneca, Plc.
Medtronic
Takeda Pharmaceutical Company Limited
The Kroger Co.
GlaxoSmithKline
Pfizer
Merck
Novartis AG
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Type
H2 Receptor Antagonist
Proton Pump Inhibitor (PPi)
Antacids
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Application
Clinic
Hospital
Medical Center
Others
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Gastro Esophageal Reflux Disease (GERD) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gastro Esophageal Reflux Disease (GERD) Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gastro Esophageal Reflux Disease (GERD) Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Gastro Esophageal Reflux Disease (GERD) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastro Esophageal Reflux Disease (GERD) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastro Esophageal Reflux Disease (GERD) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastro Esophageal Reflux Disease (GERD) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastro Esophageal Reflux Disease (GERD) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastro Esophageal Reflux Disease (GERD) Drug industry.
Chapter 3: Detailed analysis of Gastro Esophageal Reflux Disease (GERD) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gastro Esophageal Reflux Disease (GERD) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gastro Esophageal Reflux Disease (GERD) Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Gastro Esophageal Reflux Disease (GERD) Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Gastro Esophageal Reflux Disease (GERD) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Gastro Esophageal Reflux Disease (GERD) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Gastro Esophageal Reflux Disease (GERD) Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Gastro Esophageal Reflux Disease (GERD) Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Gastro Esophageal Reflux Disease (GERD) Drug market include Addex Therapeutics, Aros Pharma, AstraZeneca, Plc., Medtronic, Takeda Pharmaceutical Company Limited, The Kroger Co., GlaxoSmithKline, Pfizer and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Gastro Esophageal Reflux Disease (GERD) Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastro Esophageal Reflux Disease (GERD) Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastro Esophageal Reflux Disease (GERD) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastro Esophageal Reflux Disease (GERD) Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastro Esophageal Reflux Disease (GERD) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastro Esophageal Reflux Disease (GERD) Drug sales, projected growth trends, production technology, application and end-user industry.
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Company
Addex Therapeutics
Aros Pharma
AstraZeneca, Plc.
Medtronic
Takeda Pharmaceutical Company Limited
The Kroger Co.
GlaxoSmithKline
Pfizer
Merck
Novartis AG
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Type
H2 Receptor Antagonist
Proton Pump Inhibitor (PPi)
Antacids
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Application
Clinic
Hospital
Medical Center
Others
Gastro Esophageal Reflux Disease (GERD) Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Gastro Esophageal Reflux Disease (GERD) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gastro Esophageal Reflux Disease (GERD) Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gastro Esophageal Reflux Disease (GERD) Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Gastro Esophageal Reflux Disease (GERD) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastro Esophageal Reflux Disease (GERD) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastro Esophageal Reflux Disease (GERD) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastro Esophageal Reflux Disease (GERD) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastro Esophageal Reflux Disease (GERD) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastro Esophageal Reflux Disease (GERD) Drug industry.
Chapter 3: Detailed analysis of Gastro Esophageal Reflux Disease (GERD) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gastro Esophageal Reflux Disease (GERD) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gastro Esophageal Reflux Disease (GERD) Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2020-2031)
- 1.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume (2020-2031)
- 1.2.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Gastro Esophageal Reflux Disease (GERD) Drug Market Dynamics
- 2.1 Gastro Esophageal Reflux Disease (GERD) Drug Industry Trends
- 2.2 Gastro Esophageal Reflux Disease (GERD) Drug Industry Drivers
- 2.3 Gastro Esophageal Reflux Disease (GERD) Drug Industry Opportunities and Challenges
- 2.4 Gastro Esophageal Reflux Disease (GERD) Drug Industry Restraints
- 3 Gastro Esophageal Reflux Disease (GERD) Drug Market by Company
- 3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Revenue Ranking in 2024
- 3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Revenue by Company (2020-2025)
- 3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Company (2020-2025)
- 3.4 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price by Company (2020-2025)
- 3.5 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Ranking (2023-2025)
- 3.6 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Manufacturing Base and Headquarters
- 3.7 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Product Type and Application
- 3.8 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Gastro Esophageal Reflux Disease (GERD) Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Gastro Esophageal Reflux Disease (GERD) Drug Market by Type
- 4.1 Gastro Esophageal Reflux Disease (GERD) Drug Type Introduction
- 4.1.1 H2 Receptor Antagonist
- 4.1.2 Proton Pump Inhibitor (PPi)
- 4.1.3 Antacids
- 4.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type
- 4.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type
- 4.3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type (2020-2031)
- 5 Gastro Esophageal Reflux Disease (GERD) Drug Market by Application
- 5.1 Gastro Esophageal Reflux Disease (GERD) Drug Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Medical Center
- 5.1.4 Others
- 5.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application
- 5.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application
- 5.3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application (2020-2031)
- 6 Gastro Esophageal Reflux Disease (GERD) Drug Regional Sales and Value Analysis
- 6.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region (2020-2031)
- 6.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region: 2020-2025
- 6.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region (2026-2031)
- 6.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region (2026-2031)
- 6.5 Global Gastro Esophageal Reflux Disease (GERD) Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2020-2031)
- 6.6.2 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2020-2031)
- 6.7.2 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2020-2031)
- 6.9.2 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2024 VS 2031
- 7 Gastro Esophageal Reflux Disease (GERD) Drug Country-level Sales and Value Analysis
- 7.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2020-2031)
- 7.3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2020-2025)
- 7.3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2026-2031)
- 7.4 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Addex Therapeutics
- 8.1.1 Addex Therapeutics Comapny Information
- 8.1.2 Addex Therapeutics Business Overview
- 8.1.3 Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.1.5 Addex Therapeutics Recent Developments
- 8.2 Aros Pharma
- 8.2.1 Aros Pharma Comapny Information
- 8.2.2 Aros Pharma Business Overview
- 8.2.3 Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.2.5 Aros Pharma Recent Developments
- 8.3 AstraZeneca, Plc.
- 8.3.1 AstraZeneca, Plc. Comapny Information
- 8.3.2 AstraZeneca, Plc. Business Overview
- 8.3.3 AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.3.5 AstraZeneca, Plc. Recent Developments
- 8.4 Medtronic
- 8.4.1 Medtronic Comapny Information
- 8.4.2 Medtronic Business Overview
- 8.4.3 Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.4.5 Medtronic Recent Developments
- 8.5 Takeda Pharmaceutical Company Limited
- 8.5.1 Takeda Pharmaceutical Company Limited Comapny Information
- 8.5.2 Takeda Pharmaceutical Company Limited Business Overview
- 8.5.3 Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.5.5 Takeda Pharmaceutical Company Limited Recent Developments
- 8.6 The Kroger Co.
- 8.6.1 The Kroger Co. Comapny Information
- 8.6.2 The Kroger Co. Business Overview
- 8.6.3 The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.6.4 The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.6.5 The Kroger Co. Recent Developments
- 8.7 GlaxoSmithKline
- 8.7.1 GlaxoSmithKline Comapny Information
- 8.7.2 GlaxoSmithKline Business Overview
- 8.7.3 GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.7.4 GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.7.5 GlaxoSmithKline Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Comapny Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 Merck
- 8.9.1 Merck Comapny Information
- 8.9.2 Merck Business Overview
- 8.9.3 Merck Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Merck Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.9.5 Merck Recent Developments
- 8.10 Novartis AG
- 8.10.1 Novartis AG Comapny Information
- 8.10.2 Novartis AG Business Overview
- 8.10.3 Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
- 8.10.5 Novartis AG Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Gastro Esophageal Reflux Disease (GERD) Drug Value Chain Analysis
- 9.1.1 Gastro Esophageal Reflux Disease (GERD) Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gastro Esophageal Reflux Disease (GERD) Drug Sales Mode & Process
- 9.2 Gastro Esophageal Reflux Disease (GERD) Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gastro Esophageal Reflux Disease (GERD) Drug Distributors
- 9.2.3 Gastro Esophageal Reflux Disease (GERD) Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.